الوصف
Baseline demographic and clinical characteristics of children with allergic rhinoconjunctivitis enrolled in the Lertal prevention trial are compared between treatment and control groups.
Figure 2
Source Paper
A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II.Cite This Figure
![Figure 2: Baseline demographic and clinical characteristics of children with allergic rhinoconjunctivitis enrolled in the Lertal prevention trial are compared between treatment and control groups.]() > Source: Gianluigi Marseglia et al. "A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nu." *Italian journal of pediatrics*, 2019. PMID: [31319883](https://pubmed.ncbi.nlm.nih.gov/31319883/)
<figure> <img src="" alt="Baseline demographic and clinical characteristics of children with allergic rhinoconjunctivitis enrolled in the Lertal prevention trial are compared between treatment and control groups." /> <figcaption>Figure 2. Baseline demographic and clinical characteristics of children with allergic rhinoconjunctivitis enrolled in the Lertal prevention trial are compared between treatment and control groups.<br> Source: Gianluigi Marseglia et al. "A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nu." <em>Italian journal of pediatrics</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31319883/">31319883</a></figcaption> </figure>